Last reviewed · How we verify
NCT05679180: MICROPULSE
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
NA trial testing micropulse laser in Central Serous Chorioretinopathy. Withdrawn.
24 May 2023
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 11 May 2023 |
| Primary completion | 24 May 2023 |
| Estimated completion | 24 May 2023 |
Drugs / interventions tested
- micropulse laser
Conditions studied
- Central Serous Chorioretinopathy — all drugs for Central Serous Chorioretinopathy →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Central Serous Chorioretinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05679180
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of micropulse laser
Trials testing the same drug.
- NCT04014556 — Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema · NA · completed
Other recruiting trials for Central Serous Chorioretinopathy
Currently open trials in the same condition.
- NCT06527326 — the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy · NA · recruiting
- NCT06346405 — Central Serous Chorioretinopathy and Micropulse Laser Treatment · recruiting
- NCT05570591 — Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy · NA · recruiting
- NCT05589974 — Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy · recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05679180 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 30 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679180.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing